Anti-OX40 Antibody PF-04518600

Phase 2Biologic

UUniversity of Southern California

Anti-OX40 Antibody PF-04518600 is one of 76 biologic programs targeting Kidney Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Kidney CancerActive, not recruiting

Breast CancerActive, not recruiting

Kidney CancerPhase 2

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Trodelvy

Gilead

Preclinical

37 2

Halaven

Eisai

Preclinical

38 3

Megace

Bristol-Myers Squibb

Preclinical

4 4

MS Contin

Merck & Co.

Preclinical

2 5

Zolymbus

AbbVie

Preclinical

1 6

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 7

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 8

Zinecard

CChildren's Oncology Group

Preclinical

2 9

Effexor

WWyeth-Lederle Vaccines

Preclinical

2 10

Anti-OX40 Antibody PF-04518600

UUniversity of Southern California

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Kidney Cancer

NCT03092856

Clinical

Trials by Indication[1]

Breast Cancer1 trial

Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer

Recruiting·LLaura Huppert, MD, BA·Phase 2·NCT03971409·150 enrolled

Kidney Cancer1 trial

Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer

Active, not recruiting·UUniversity of Southern California·Phase 2·NCT03092856·62 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Anti-OX40 Antibody PF-04518600. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Anti-OX40 Antibody PF-04518600 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Anti-OX40 Antibody PF-04518600. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Southern California company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Southern California

Anti-OX40 Antibody PF-04518600

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Breast Cancer1 trial

Kidney Cancer1 trial

References

Drug Info

Quick Facts

Related News